3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Breast Neoplasms
2
Scleroderma, Localized
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Pneumonia
1
Neurodermatitis
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lichen Planus
1
Leukemia
1
Keratoacanthoma
1
Keloid
1
Hemangioma
1
Granuloma Annulare
1
Dermoid Cyst
1
Dendritic Cell Sarcoma, Interdigitating
1
Cicatrix, Hypertrophic
1
Cancer Pain
1
Bone Neoplasms
1
Asthma
1
Arthritis, Rheumatoid
1
Alopecia Areata
1
Interventions
Adalimumab
13
Etanercept
8
Methotrexate
7
Rituximab
6
Abatacept
6
tocilizumab
5
golimumab
5
tofacitinib
4
olokizumab
4
Certolizumab Pegol
4
Tumor Necrosis Factor Inhibitors
3
Infliximab
3
Saline Solution
2
Antirheumatic Agents
2
upadacitinib
1
secukinumab
1
sarilumab
1
mavrilimumab
1
baricitinib
1
Vitamin D
1
Vaccines
1
TACI receptor-IgG Fc fragment fusion protein
1
Syringes
1
Sulfasalazine
1
Sodium Chloride
1
Radioimmunodetection
1
RC-18
1
Pharmaceutical Preparations
1
Lysine Acetyltransferase 5
1
Leflunomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Arthritis, Rheumatoid
×
Adrenal Cortex Hormones
×
Clear all
NCT02046603
2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3
Completed
162 enrolled
30 charts